Skip to main content
SpringerLink
Log in

Substance-Induced Psychosis and Co-occurring Psychotic Disorders

  • Chapter
  • First Online:
Substance Use and the Acute Psychiatric Patient

Part of the book series: Current Clinical Psychiatry ((CCPSY))

Abstract

Distinguishing between substance-induced psychosis (SIP) and a primary psychotic illness in the emergency setting can be difficult but important for making treatment and disposition decisions. Many different substances can cause psychosis during periods of intoxication, withdrawal, or both. In the acute setting, a thorough yet targeted clinical history with a review of certain objective findings is a strategy for differentiating between SIP and a primary psychotic disorder with or without comorbid substance use. Specific behavioral and pharmacologic interventions are necessary for treating agitation and psychosis, occurring either in the setting of SIP or primary psychotic disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Larkin GL, Claassen CA, Emond JA, Pelletier AJ, Camargo CA. Trends in U.S. emergency department visits for mental health conditions, 1992 to 2001. Psychiatr Serv. 2005;56(6):671–7.

    Article  Google Scholar 

  2. Sara GE, Burgess PM, Malhi GS, Whiteford HA, Hall WC. Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Aust N Z J Psychiatry. 2014;48(11):1036–47.

    Article  Google Scholar 

  3. Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005;58(8):668–76.

    Article  Google Scholar 

  4. Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, et al. Substance abuse in first-episode non-affective psychosis. Schizophr Res. 2006;88(1–3):55–62.

    Article  Google Scholar 

  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.

    Book  Google Scholar 

  6. Niemi-Pynttari JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013;74(1):e94–9.

    Article  Google Scholar 

  7. Ross JD, Gastfriend DR, Renner JA. Massachusetts General Hospital handbook of general hospital psychiatry. 6th ed. Philadelphia: Saunders/Elselvier; 2010.

    Google Scholar 

  8. Mirijello A, D'Angelo C, Ferrulli A, Vassallo G, Antonelli M, Caputo F, et al. Identification and management of alcohol withdrawal syndrome. Drugs. 2015;75(4):353–65.

    Article  CAS  Google Scholar 

  9. Perala J, Kuoppasalmi K, Pirkola S, Harkanen T, Saarni S, Tuulio-Henriksson A, et al. Alcohol-induced psychotic disorder and delirium in the general population. Br J Psychiatry. 2010;197(3):200–6.

    Article  Google Scholar 

  10. Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med. 2014;371(22):2109–13.

    Article  Google Scholar 

  11. Perry EC. Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs. 2014;28(5):401–10.

    Article  CAS  Google Scholar 

  12. Petursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89(11):1455–9.

    Article  CAS  Google Scholar 

  13. Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull. 1992;18(1):115–22.

    Article  CAS  Google Scholar 

  14. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13(2):181–90.

    Article  Google Scholar 

  15. Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol. 2012;7(1):113–39.

    Article  Google Scholar 

  16. Thirthalli J, Benegal V. Psychosis among substance users. Curr Opin Psychiatry. 2006;19(3):239–45.

    Article  Google Scholar 

  17. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014;28(12):1115–26.

    Article  CAS  Google Scholar 

  18. Roncero C, Daigre C, Grau-Lopez L, Barral C, Perez-Pazos J, Martinez-Luna N, et al. An international perspective and review of cocaine-induced psychosis: a call to action. Subst Abus. 2014;35(3):321–7.

    Article  Google Scholar 

  19. Manschreck TC, Laughery JA, Weisstein CC, Allen D, Humblestone B, Neville M, et al. Characteristics of freebase cocaine psychosis. Yale J Biol Med. 1988;61(2):115–22.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. SAMHSA. Treatment for stimulant use disorders. Rawson RA, editor. Rockville; 1999.

    Google Scholar 

  21. Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Hsiao CC, et al. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 2003;33(8):1407–14.

    Article  CAS  Google Scholar 

  22. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend. 1996;42(3):201–7.

    Article  CAS  Google Scholar 

  23. Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. Int Rev Psychiatry. 2009;21(2):152–62.

    Article  Google Scholar 

  24. Nunez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr Scand. 2002;105(3):173–8.

    Article  CAS  Google Scholar 

  25. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. Br Med J. 2011;342:d738.

    Article  Google Scholar 

  26. Hall W, Degenhardt L. Cannabis use and psychosis: a review of clinical and epidemiological evidence. Aust N Z J Psychiatry. 2000;34(1):26–34.

    Article  CAS  Google Scholar 

  27. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–28.

    Article  Google Scholar 

  28. Schanzer BM, First MB, Dominguez B, Hasin DS, Caton CL. Diagnosing psychotic disorders in the emergency department in the context of substance use. Psychiatr Serv. 2006;57(10):1468–73.

    Article  Google Scholar 

  29. Drake RE, Caton CL, Xie H, Hsu E, Gorroochurn P, Samet S, et al. A prospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis. Am J Psychiatry. 2011;168(7):742–8.

    Article  Google Scholar 

  30. Caton CL, Drake RE, Hasin DS, Dominguez B, Shrout PE, Samet S, et al. Differences between early-phase primary psychotic disorders with concurrent substance use and substance-induced psychoses. Arch Gen Psychiatry. 2005;62(2):137–45.

    Article  Google Scholar 

  31. Caton CL, Hasin DS, Shrout PE, Drake RE, Dominguez B, First MB, et al. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Br J Psychiatry. 2007;190:105–11.

    Article  Google Scholar 

  32. Weibell MA, Joa I, Bramness J, Johannessen JO, McGorry PD, Ten Velden Hegelstad W, et al. Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area. BMC Psychiatry. 2013;13:319.

    Article  Google Scholar 

  33. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry. 1996;153(9):1195–201.

    Article  CAS  Google Scholar 

  34. Spinelli E, Barnes AJ, Young S, Castaneto MS, Martin TM, Klette KL, et al. Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids. Drug Test Anal. 2015;7(6):467–74.

    Article  CAS  Google Scholar 

  35. Sweeney B, Talebi S, Toro D, Gonzalez K, Menoscal JP, Shaw R, et al. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med. 2016;34(1):121 e1–2.

    Article  Google Scholar 

  36. Paterson NE, Darby WC, Sandhu PS. N,N-dimethyltryptamine-induced psychosis. Clin Neuropharmacol. 2015;38(4):141–3.

    Article  CAS  Google Scholar 

  37. Leelahanaj T, Kongsakon R, Netrakom P. A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis. J Med Assoc Thai. 2005;88(Suppl 3):S43–52. PubMed: 16858942.

    Google Scholar 

  38. Verachai V, Rukngan W, Chawanakrasaesin K, Nilaban S, Suwanmajo S, Thanateerabunjong R, et al. Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacology (Berl). 2014;231(16):3099–108.

    Article  CAS  Google Scholar 

  39. Farnia V, Shakeri J, Tatari F, Juibari TA, Yazdchi K, Bajoghli H, et al. Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis. Am J Drug Alcohol Abuse. 2014;40(1):10–5.

    Article  Google Scholar 

  40. Bui QM, Simpson S, Nordstrom K. Psychiatric and medical management of marijuana intoxication in the emergency department. West J Emer Med. 2015;16(3):414–7.

    Article  Google Scholar 

  41. Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup. West J Emerg Med. 2012;13(1):26–34.

    Article  Google Scholar 

  42. Zacher JL, Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam. J Clin Psychiatry. 2005;66(12):1614–5.

    Article  Google Scholar 

  43. Christopher PP, Pinals DA, Stayton T, Sanders K, Blumberg L. Nature and utilization of civil commitment for substance abuse in the United States. J Am Acad Psychiatry Law. 2015;43(3):313–20.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wellness and Recovery After Psychosis Program, Boston Medical Center, Boston, MA, USA

    Hannah E. Brown

  2. Boston University School of Medicine, Boston, MA, USA

    Hannah E. Brown

  3. Department of Psychiatry, First Episode and Early Psychosis Program, Massachusetts General Hospital, Boston, MA, USA

    Yoshio Kaneko & Abigail L. Donovan

  4. Harvard Medical School, Boston, MA, USA

    Yoshio Kaneko & Abigail L. Donovan

  5. Transitional Age Youth Clinic, Massachusetts General Hospital, Boston, MA, USA

    Yoshio Kaneko

  6. Newton-Wellesley Hospital, Newton, MA, USA

    Yoshio Kaneko

  7. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

    Abigail L. Donovan

  8. Acute Psychiatry Service, Massachusetts General Hospital, Boston, MA, USA

    Abigail L. Donovan

Authors
  1. Hannah E. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshio Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abigail L. Donovan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah E. Brown .

Editor information

Editors and Affiliations

  1. Massachusetts General Hospital, Boston, MA, USA

    Abigail L. Donovan

  2. Massachusetts General Hospital, Boston, MA, USA

    Suzanne A. Bird

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Brown, H.E., Kaneko, Y., Donovan, A.L. (2019). Substance-Induced Psychosis and Co-occurring Psychotic Disorders. In: Donovan, A., Bird, S. (eds) Substance Use and the Acute Psychiatric Patient. Current Clinical Psychiatry. Humana, Cham. https://doi.org/10.1007/978-3-319-23961-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23961-3_7

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-319-23960-6

  • Online ISBN: 978-3-319-23961-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation